The World Health Organization on Monday issued its first guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment for the condition, which affects more than 1 billion people globally according to the agency. Reuters first reported that the WHO was likely to take this step earlier this year. The guidance comes as demand for the class of drugs known as GLP-1 agonists has surged worldwide, and governments are figuring out how to include the blockbuster therapies into public health systems...